Dermapharm Holding SE (ETR:DMPG) on Tuesday confirmed its full-year 2025 guidance, projecting flat revenue growth in the second half and an adjusted EBITDA increase of about 10%, after reporting a 3% decline in second-quarter sales.
The pharma company said revenue for the quarter came in at €272 million, down from the previous year, as a 30% drop in parallel imports to €46 million offset growth in other areas.
Sales in branded pharmaceuticals rose 6% to €143 million, while other healthcare products increased 4% to €84 million.
Adjusted EBITDA rose 4% to €66.7 million, equal to a margin of 24.5%, compared with 23% in the same period last year. Branded pharmaceuticals delivered €60.4 million in adjusted EBITDA with a margin of 42.4%, up from 40.9%.
Other healthcare products reported €8.6 million in adjusted EBITDA, down 14% from last year, with a margin of 10.3%, compared with 12.4% previously.
Parallel imports recorded a loss of €0.7 million, with margin negative at 1.5%, after a margin of 1.4% last year.
Operating cash flow rose to €65.9 million from €22.9 million a year earlier. Free cash flow increased to €55.9 million from €14.1 million, supported by lower working capital demand.
The Grünwald-based company said full-year guidance remains unchanged. It calls for second-half revenue to remain flat but adjusted EBITDA to rise toward the midpoint of its target range, with margin improving to 29.6% from 25.8% in the first half of the year.
Source :
https://www.investing.com/news/earnings/dermapharm-confirms-2025-outlook-as-q2-sales-slip-but-profits-edge-higher-4210223
